0001193125-22-108777.txt : 20220419 0001193125-22-108777.hdr.sgml : 20220419 20220419084157 ACCESSION NUMBER: 0001193125-22-108777 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220418 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220419 DATE AS OF CHANGE: 20220419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Checkmate Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001651431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 364813934 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39425 FILM NUMBER: 22833554 BUSINESS ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 978-503-2124 MAIL ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 d343647d8k.htm 8-K 8-K
false 0001651431 0001651431 2022-04-18 2022-04-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 19, 2022 (April 18, 2022)

 

 

CHECKMATE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39425   36-4813934
(State or other jurisdiction of
incorporation or organization)		  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

Checkmate Pharmaceuticals, Inc.

245 Main Street, 2nd Floor
Cambridge, Massachusetts 02142
(Address of Principal Executive Offices) (Zip Code)

(617) 682-3625

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   CMPI   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

☒

Emerging Growth Company

 

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

Item 8.01

Other Events.

On April 19, 2022, Checkmate Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Regeneron Pharmaceuticals, Inc., a New York corporation (“Parent”), issued a joint press release announcing the execution of an Agreement and Plan of Merger (the “Merger Agreement”), dated April 18, 2022, by and among the Company, Parent, and Scandinavian Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent. A copy of the joint press release is attached as Exhibit 99.1 to this report and incorporated herein by reference.

Forward-Looking Statements

This communication includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron”) and Checkmate Pharmaceuticals, Inc. (“Checkmate”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Risks that may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Checkmate’s stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; the possibility that the transaction does not close; risks related to Regeneron’s ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period and that Regeneron and Checkmate will not be integrated successfully; the effects of the transaction on relationships with employees, other business partners or governmental entities; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Regeneron’s or Checkmate’s common stock and/or Regeneron’s or Checkmate’s operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition; the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron’s or Checkmate’s business and its employees, collaborators, and suppliers and other third parties on which Regeneron and Checkmate rely; Regeneron’s, Checkmate’s, and their collaborators’ ability to continue to conduct research and clinical programs; Regeneron’s and Checkmate’s ability to manage their supply chains; Regeneron’s ability to manage net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”); the nature, timing, and possible success and therapeutic applications of Regeneron’s Products, product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”), and product candidates being developed by Checkmate, such as vidutolimod; the extent to which the results from the research and development programs conducted by Regeneron,

Checkmate, and/or their collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the potential of the Toll-like receptor 9 (TLR9) agonist technology discussed in this press release; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products, Regeneron’s Product Candidates, and vidutolimod and the impact of studies (whether conducted by Regeneron, Checkmate or others and whether mandated or voluntary) on any of the foregoing or any potential regulatory approval of Regeneron’s Products, Regeneron’s Product Candidates, and vidutolimod; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and vidutolimod and new indications for Regeneron’s Products; the ability of Regeneron’s and Checkmate’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products, Regeneron’s Product Candidates, and vidutolimod; the ability of Regeneron and/or its collaborators to manufacture and manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron’s Products, Regeneron’s Product Candidates, and vidutolimod in patients, including serious complications or side effects in connection with the use of Regeneron’s Products, Regeneron’s Product Candidates, and vidutolimod in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products, Regeneron’s Product Candidates, or Checkmate’s ability to continue to develop or commercialize vidutolimod; and competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products, Regeneron’s Product Candidates, or vidutolimod. A more complete description of these and other material risks can be found in Regeneron’s and Checkmate’s filings with the U.S. Securities and Exchange Commission, including their Forms 10-K for the year ended December 31, 2021 as well as the Schedule TO and related tender offer documents to be filed by Regeneron and Scandinavian Acquisition Sub, Inc., and the Schedule 14D-9 to be filed by Checkmate, and, if applicable, the proxy statement referenced below. Any forward-looking statements are made based on the current beliefs and judgments of Regeneron’s and Checkmate’s management, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron or Checkmate. Regeneron and Checkmate do not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Additional Information and Where to Find It

The tender offer referenced in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Checkmate, nor is it a substitute for the tender offer materials that Checkmate, Regeneron or its acquisition subsidiary, Scandinavian Acquisition Sub, Inc., will file with the Securities and Exchange Commission (“SEC”). The solicitation and offer to buy Checkmate stock will only be made pursuant to an Offer to Purchase and related tender offer materials that Regeneron intends to file with the SEC. At the time the tender offer is commenced, Regeneron and its acquisition subsidiary will file a Tender Offer Statement on Schedule TO and thereafter Checkmate will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Under certain circumstances described in the definitive transaction documents, Regeneron may determine to instead to terminate or withdraw the offer and effect the transaction through a merger only, in which case the relevant documents to be filed with the SEC will include a proxy statement for the solicitation of votes of Checkmate stockholders to approve the merger. CHECKMATE’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ CAREFULLY THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AND, IF APPLICABLE, THE PROXY STATEMENT BECAUSE THEY WILL EACH CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF CHECKMATE SECURITIES AND OTHER INVESTORS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING WITH RESPECT TO THE TENDER OFFER, OR, IF APPLICABLE, VOTING ON THE TRANSACTION. The Offer to Purchase, the related Letter of Transmittal, certain other tender offer documents, as well as the Solicitation/Recommendation Statement, and if applicable, the proxy statement will be made available to all stockholders of Checkmate at no expense to them and will also be made available for free at the SEC’s website at www.sec.gov. Additional copies may be obtained for free by contacting either Regeneron or Checkmate. Copies of the documents filed with the SEC by Checkmate will be available free of charge on Checkmate’s website at https://ir.checkmatepharma.com or by contacting Checkmate’s Investor Relations Department at (617) 682-3625. Copies of the documents filed with the SEC by Regeneron will be available free of charge on Regeneron’s website at https://investor.regeneron.com or by contacting Regeneron’s Investor Relations Department at invest@regeneron.com or (914) 847-7741.

In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, and if applicable, the proxy statement, Regeneron and Checkmate each file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any reports or other information filed by Regeneron or Checkmate at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Regeneron’s and Checkmate’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at http://www.sec.gov.

If the tender offer is terminated and the transaction is to be effected by merger only, in which case, the approval of Checkmate stockholders must be obtained, Regeneron, Checkmate and their respective directors and executive officers may be deemed to be participants in any such solicitation of proxies from Checkmate’s stockholders in connection with the proposed transaction. Information regarding Regeneron’s directors and executive officers is available in its proxy statement that was filed with the SEC; information regarding Checkmate’s directors and executive officers is available in its proxy statement that was filed with the SEC. Other information regarding potential participants in any such proxy solicitation will be contained in any proxy statement filed in connection with the transaction.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

Exhibit
No.		    Description of Exhibit
99.1    Joint Press Release, issued April 19, 2022.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 19, 2022

 

CHECKMATE PHARMACEUTICALS, INC.
By:  

/s/ Robert Dolski

Name:   Robert Dolski
Title:   Chief Financial Officer
 EX-99.1 2 d343647dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO    LOGO

Press Release

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Proposed ~$250 million all-cash acquisition strengthens Regeneron’s portfolio of diverse and combinable immuno-oncology candidates

Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy

Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer

Tarrytown, N.Y. and Cambridge, Mass., April 19, 2022 – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer, today announced a definitive agreement for the acquisition of Checkmate by Regeneron at an all-cash price of $10.50 per share of Checkmate common stock. The proposed acquisition values Checkmate at a total equity value of approximately $250 million.

Checkmate’s lead investigational candidate is vidutolimod, an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonist delivered in a virus-like particle.

“As we continue to advance and expand our research efforts in immuno-oncology, the acquisition of Checkmate will add a promising new modality to Regeneron’s toolkit of potential approaches for difficult-to-treat cancers,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. “The unique combination of a differentiated Toll-like receptor 9 with other antibody-based oncology agents may result in increased clinical benefit and provide new treatment options for patients in need. We look forward to welcoming the Checkmate team and their complementary scientific acumen to the Regeneron family.”

“We are thrilled that Checkmate will become part of Regeneron, a biotechnology leader that shares our deep appreciation for science, hunger for ground-breaking discoveries and commitment to helping patients defeat cancer,” said Alan Bash, President and Chief Executive Officer of Checkmate.

“We believe that the data we have generated with vidutolimod positions Checkmate at the forefront of the innate immune activator field. It is our hope that Regeneron’s resources and expertise will help accelerate the development of vidutolimod and realization of the full potential of our virus-like particle (VLP) platform for immunotherapy,” said Art Krieg, M.D., Checkmate’s Founder and Chief Scientific Officer.

 

1/6

Vidutolimod is administered into the tumor and is believed to induce and expand anti-tumor T cells and induce tumor regression as a monotherapy in patients whose tumors previously progressed on PD-1 checkpoint inhibition. In the Phase 1b program, documented abscopal responses were seen in distant, un-injected lesions. Vidutolimod is an investigational therapy and has not been approved by U.S. Food and Drug Administration or any other regulatory agency.

The merger agreement provides for Regeneron, through a subsidiary, to initiate a tender offer to acquire all outstanding shares of Checkmate at an all-cash price of $10.50 per share of Checkmate common stock. The closing of the tender offer will be subject to certain conditions, including the tender of at least a majority of the outstanding shares of Checkmate common stock, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Upon the successful completion of the tender offer, Regeneron will acquire all shares not acquired in the tender through a second-step merger. The transaction is expected to close in mid-2022.

Regeneron’s legal advisor for the transaction is Wachtell, Lipton, Rosen & Katz. Centerview Partners is serving as Checkmate’s financial advisor and Goodwin Procter LLP is serving as its legal advisor.

About Vidutolimod

Vidutolimod works by two complementary mechanisms that together have a unique ability to drive a strong systemic anti-tumor T cell response. First, the virus-like particle (VLP) activates an immune response to the VLP, leading to the production of antibodies that deliver the VLP into plasmacytoid dendritic cells (pDC) and other immune cells via specialized receptors called FcRs. This provides an initial stimulatory signal to pDC and brings the CpG-A to TLR9 (the receptor for CpG DNA) inside the pDC. Second, CpG-A stimulates TLR9 in a manner that induces pDC to release significantly higher levels of IFN- α and other type I interferons than other innate immune activators, resulting in a stronger anti-tumor T cell response.

Animal models and in vitro experiments suggest that, when activated by vidutolimod by this combination of signals, pDC recruit and coordinate a variety of other immune cells, culminating in the generation of a strong anti-tumor T cell response.

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

 

2/6

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

About Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Information regarding Checkmate Pharmaceuticals is available at www.checkmatepharma.com.

Forward-looking Statements

This communication includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron”) and Checkmate Pharmaceuticals, Inc. (“Checkmate”) and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Risks that may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Checkmate’s stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; the possibility that the transaction does not close; risks related to Regeneron’s ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period and that Regeneron and Checkmate will not be integrated successfully; the effects of the transaction on relationships with employees, other business partners or governmental entities; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Regeneron’s or Checkmate’s common stock and/or Regeneron’s or Checkmate’s operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition; the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron’s or Checkmate’s business and its employees, collaborators, and suppliers and other third parties on which Regeneron and Checkmate rely; Regeneron’s, Checkmate’s, and their collaborators’ ability to continue to conduct research and clinical programs; Regeneron’s and Checkmate’s ability to manage their supply chains; Regeneron’s ability to manage net product sales of products marketed or otherwise commercialized by Regeneron and/or its

 

3/6

collaborators or licensees (collectively, “Regeneron’s Products”); the nature, timing, and possible success and therapeutic applications of Regeneron’s Products, product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”), and product candidates being developed by Checkmate, such as vidutolimod; the extent to which the results from the research and development programs conducted by Regeneron, Checkmate, and/or their collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the potential of the Toll-like receptor 9 (TLR9) agonist technology discussed in this press release; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products, Regeneron’s Product Candidates, and vidutolimod and the impact of studies (whether conducted by Regeneron, Checkmate or others and whether mandated or voluntary) on any of the foregoing or any potential regulatory approval of Regeneron’s Products, Regeneron’s Product Candidates, and vidutolimod; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and vidutolimod and new indications for Regeneron’s Products; the ability of Regeneron’s and Checkmate’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products, Regeneron’s Product Candidates, and vidutolimod; the ability of Regeneron and/or its collaborators to manufacture and manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron’s Products, Regeneron’s Product Candidates, and vidutolimod in patients, including serious complications or side effects in connection with the use of Regeneron’s Products, Regeneron’s Product Candidates, and vidutolimod in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products, Regeneron’s Product Candidates, or Checkmate’s ability to continue to develop or commercialize vidutolimod; and competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products, Regeneron’s Product Candidates, or vidutolimod. A more complete description of these and other material risks can be found in Regeneron’s and Checkmate’s filings with the U.S. Securities and Exchange Commission, including their Forms 10-K for the year ended December 31, 2021 as well as the Schedule TO and related tender offer documents to be filed by Regeneron and Scandinavian Acquisition Sub, Inc. and the Schedule 14D-9 to be filed by Checkmate, and, if applicable, the proxy statement referenced below. Any forward-looking statements are made based on the current beliefs and judgments of Regeneron’s and Checkmate’s management, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron or Checkmate. Regeneron and Checkmate do not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Additional Information and Where to Find It

The tender offer referenced in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Checkmate, nor is it a substitute for the tender offer materials that Checkmate, Regeneron or its acquisition subsidiary, Scandinavian Acquisition Sub, Inc. will file with the Securities and Exchange Commission (“SEC”). The solicitation and offer to buy Checkmate stock will only be made pursuant to an Offer to Purchase and related

 

4/6

tender offer materials that Regeneron intends to file with the SEC. At the time the tender offer is commenced, Regeneron and its acquisition subsidiary will file a Tender Offer Statement on Schedule TO and thereafter Checkmate will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Under certain circumstances described in the definitive transaction documents, Regeneron may determine to instead to terminate or withdraw the offer and effect the transaction through a merger only, in which case the relevant documents to be filed with the SEC will include a proxy statement for the solicitation of votes of Checkmate stockholders to approve the merger. CHECKMATE’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ CAREFULLY THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AND, IF APPLICABLE, THE PROXY STATEMENT BECAUSE THEY WILL EACH CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF CHECKMATE SECURITIES AND OTHER INVESTORS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING WITH RESPECT TO THE TENDER OFFER, OR, IF APPLICABLE, VOTING ON THE TRANSACTION. The Offer to Purchase, the related Letter of Transmittal, certain other tender offer documents, as well as the Solicitation/Recommendation Statement, and if applicable, the proxy statement will be made available to all stockholders of Checkmate at no expense to them and will also be made available for free at the SEC’s website at www.sec.gov. Additional copies may be obtained for free by contacting either Regeneron or Checkmate. Copies of the documents filed with the SEC by Checkmate will be available free of charge on Checkmate’s website at https://ir.checkmatepharma.com or by contacting Checkmate’s Investor Relations Department at (617) 682-3625. Copies of the documents filed with the SEC by Regeneron will be available free of charge on Regeneron’s website at https://investor.regeneron.com or by contacting Regeneron’s Investor Relations Department at invest@regeneron.com or (914) 847-7741.

In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, and if applicable, the proxy statement, Regeneron and Checkmate each file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any reports or other information filed by Regeneron or Checkmate at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Regeneron’s and Checkmate’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at http://www.sec.gov.

If the tender offer is terminated and the transaction is to be effected by merger only, in which case, the approval of Checkmate stockholders must be obtained, Regeneron, Checkmate and their respective directors and executive officers may be deemed to be participants in any such solicitation of proxies from Checkmate’s stockholders in connection with the proposed transaction. Information regarding Regeneron’s directors and executive officers is available in its proxy statement that was filed with the SEC; information regarding Checkmate’s directors and executive officers is available in its proxy statement that was filed with the SEC. Other information regarding potential participants in any such proxy solicitation will be contained in any proxy statement filed in connection with the transaction.

 

5/6

Regeneron Media Relations

Alexandra Bowie

Tel: +1 914-847-3407

Alexandra.bowie@regeneron.com

Regeneron Investor Relations

Vesna Tosic

Tel: +1 914-847-5443

vesna.tosic@regeneron.com

Checkmate Media Contact

Karen Sharma

MacDougall Advisors

Tel: +1 781-235-3060

ksharma@macdougall.bio

Checkmate Investor Contact

Rob Dolski

Chief Financial Officer

rdolski@checkmatepharma.com

 

6/6

EX-101.SCH 3 cmpi-20220418.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cmpi-20220418_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 cmpi-20220418_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g343647110001.jpg GRAPHIC begin 644 g343647110001.jpg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end GRAPHIC 7 g343647g84d85.jpg GRAPHIC begin 644 g343647g84d85.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 18, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001651431
Document Type 8-K
Document Period End Date Apr. 18, 2022
Entity Registrant Name CHECKMATE PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39425
Entity Tax Identification Number 36-4813934
Entity Address, Address Line One 245 Main Street
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code (617)
Local Phone Number 682-3625
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol CMPI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 9 d343647d8k_htm.xml IDEA: XBRL DOCUMENT 0001651431 2022-04-18 2022-04-18 false 0001651431 8-K 2022-04-18 CHECKMATE PHARMACEUTICALS, INC. DE 001-39425 36-4813934 245 Main Street 2nd Floor Cambridge MA 02142 (617) 682-3625 false false false false Common Stock, par value $0.0001 per share CMPI NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d343647d8k.htm cmpi-20220418.xsd cmpi-20220418_lab.xml cmpi-20220418_pre.xml d343647dex991.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d343647d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d343647d8k.htm" ] }, "labelLink": { "local": [ "cmpi-20220418_lab.xml" ] }, "presentationLink": { "local": [ "cmpi-20220418_pre.xml" ] }, "schema": { "local": [ "cmpi-20220418.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cmpi", "nsuri": "http://www.checkmatepharma.com/20220418", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d343647d8k.htm", "contextRef": "duration_2022-04-18_to_2022-04-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d343647d8k.htm", "contextRef": "duration_2022-04-18_to_2022-04-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.checkmatepharma.com//20220418/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0001193125-22-108777-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-108777-xbrl.zip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